 "Revolutionizing Vision: India’s First Eye Drops for Presbyopia Approved!")
Entod Pharmaceuticals has received approval from the Drug Controller General of India to launch PresVu eye drops, a treatment for presbyopia, which commonly affects people over 40. This innovative eye drop aims to reduce reliance on reading glasses and will be available in India starting in October. The company, led by CEO Nikkhil K Masurkar, plans to focus on both domestic and emerging markets, particularly in Africa and Southeast Asia, where access to affordable medications is limited. Entod aims to create innovative products in India for global licensing, and it is also considering expanding into mental health in the future. This move marks a significant step in improving eye care and addressing the needs of millions with presbyopia worldwide.
Entod Pharmaceuticals has recently announced that it has received approval from the Drug Controller General of India (DCGI) to Market its new eye drops, PresVu, designed for treating presbyopia. This marks an important milestone for the Mumbai-based company, as PresVu will be the first eye drop in India specifically created to help people reduce their reliance on reading glasses, particularly for those over the age of 40. The eye drops are expected to hit the domestic Market in the first week of October.
The approval from DCGI follows a recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Entod Pharmaceuticals’ CEO, Nikkhil K Masurkar, expressed that this achievement is a significant step toward enhancing eye care in India and aims to provide better visual independence for millions of people struggling with this common age-related condition.
Masurkar highlighted the importance of innovating healthcare solutions not just in India but also in emerging markets like Africa and Southeast Asia, where access to affordable medicines is often a challenge. The company is focused on expanding its global footprint and plans to introduce innovative products that can make a real difference in these regions.
Furthermore, Entod Pharmaceuticals intends to explore the mental health segment in the future, recognizing the growing need for mental health solutions in India. With a solid manufacturing base in Maharashtra, the company is looking to transform healthcare by targeting three key therapeutic areas: ENT, ophthalmology, and dermatology.
This exciting development showcases Entod Pharmaceuticals’ commitment to improving eye care and addressing healthcare needs both domestically and internationally.
Tags: Entod Pharmaceuticals, DCGI approval, Presbyopia, eye drops, healthcare innovation, India, ophthalmology
What is presbyopia?
Presbyopia is a common eye condition that usually happens as people get older. It makes it harder to see things close up.
What are the new eye drops from Entod Pharmaceuticals?
Entod Pharmaceuticals has developed new eye drops that are approved by DCGI to help treat presbyopia, helping people see better up close.
What does DCGI approval mean?
DCGI approval means that the eye drops have been tested and found safe and effective for use in India by the Drug Controller General of India.
How will these eye drops help people with presbyopia?
The eye drops are designed to improve focusing ability, making it easier for people with presbyopia to read or do close-up tasks.
When will the eye drops be available for use?
Availability details might vary, but typically, approved products are made available in pharmacies soon after they receive approval.
 "Honda recalls models CB350 and H’ness CB350 for critical sensor and camshaft issues, risking braking failures; free replacements offered.")
